GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma

J Thorac Oncol. 2018 Jul;13(7):e114-e116. doi: 10.1016/j.jtho.2018.02.005.

Authors

Liang Zeng¹, Nong Yang¹, Yongchang Zhang²

Affiliations

¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
² Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China. Electronic address: [email protected].

PMID: 29935846
DOI: 10.1016/j.jtho.2018.02.005

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / administration & dosage
Adaptor Proteins, Signal Transducing
Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Aniline Compounds / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carrier Proteins / genetics*
Crizotinib / administration & dosage
Drug Resistance, Neoplasm*
Female
Gene Rearrangement*
Golgi Matrix Proteins
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Membrane Proteins / genetics*
Membrane Transport Proteins
Middle Aged
Prognosis
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / genetics*

Substances

Acrylamides
Adaptor Proteins, Signal Transducing
Aniline Compounds
Carrier Proteins
GOPC protein, human
Golgi Matrix Proteins
Membrane Proteins
Membrane Transport Proteins
Proto-Oncogene Proteins
osimertinib
Crizotinib
Protein-Tyrosine Kinases
ROS1 protein, human